Sanofi (SNY)
(Delayed Data from NSDQ)
$51.20 USD
+0.77 (1.53%)
Updated Jul 24, 2024 04:00 PM ET
Pre-Market: $52.70 +1.50 (2.93%) 8:48 AM ET
3-Hold of 5 3
B Value D Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$51.20 USD
+0.77 (1.53%)
Updated Jul 24, 2024 04:00 PM ET
Pre-Market: $52.70 +1.50 (2.93%) 8:48 AM ET
3-Hold of 5 3
B Value D Growth C Momentum C VGM
Zacks News
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
5 Value Stocks With Exciting EV-to-EBITDA Ratios to Own Now
by Anindya Barman
We have screened value stocks NMM, HPE, AEG, COWN and SNY based on the EV-to-EBITDA ratio, which offers a clearer picture of valuation and earnings potential.
Gilead (GILD) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its fourth-quarter 2022 results.
Novartis' (NVS) Unit to Acquire Astellas' Rights of Mycamine
by Zacks Equity Research
Novartis' (NVS) generic unit Sandoz is set to acquire rights to the antifungal product Mycamine from Astellas.
J&J (JNJ) Q4 Earnings Beat, Sales Miss, 2023 EPS View Upbeat
by Zacks Equity Research
J&J (JNJ) beats estimates for fourth-quarter earnings but misses the same for sales. Its EPS outlook for 2023 is above expectations while sales fall short.
Sanofi (SNY) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Sanofi (SNY) closed at $48.63, marking a -0.92% move from the previous day.
Lilly (LLY) Jardiance Kidney Disease sNDA Gets FDA Acceptance
by Zacks Equity Research
Eli Lilly's (LLY) sNDA seeks approval for diabetes medicine, Jardiance, to reduce the risk of kidney disease progression and cardiovascular death in adults with CKD.
The Zacks Analyst Blog Highlights PepsiCo, Verizon Communications, Sanofi, Vale and Paychex
by Zacks Equity Research
PepsiCo, Verizon Communications, Sanofi, Vale and Paychex are part of the Zacks top Analyst Blog.
J&J (JNJ) to Begin Q4 Earnings Season for Pharma Sector
by Zacks Equity Research
Growth in J&J's (JNJ) Pharma unit is expected to have been driven by drugs like Darzalex and Stelara. In the MedTech segment, continued recovery in worldwide procedure volume should drive sales.
Top Research Reports for PepsiCo, Verizon Communications & Sanofi
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including PepsiCo, Inc. (PEP), Verizon Communications Inc. (VZ) and The Sanofi (SNY).
J&J (JNJ) Discontinues HIV Vaccine Phase III Mosaico Study
by Zacks Equity Research
J&J (JNJ) discontinues phase III study on its investigational HIV vaccine regimen, which shows that the candidate lacks efficacy in preventing HIV.
Sanofi (SNY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Sanofi (SNY) closed the most recent trading day at $49.83, moving +1.14% from the previous trading session.
Encompass Health's (EHC) Plan Marks Entry in Rhode Island
by Zacks Equity Research
Encompass Health (EHC) aims to build a 50-bed inpatient rehabilitation hospital in Rhode Island and extend its advanced rehabilitative services suite across the Northeast.
SNY vs. NVO: Which Stock Is the Better Value Option?
by Zacks Equity Research
SNY vs. NVO: Which Stock Is the Better Value Option?
State of California Sues Insulin Makers for Unfair Practices
by Zacks Equity Research
The lawsuit aims to curb the skyrocketing cost of insulin charged by insulin manufacturers and pharmacy benefit managers companies. The State also seeks to recover some monetary compensation.
Aprea (APRE) Rises on Advancing Lead Drug to Clinical Studies
by Zacks Equity Research
Aprea Therapeutics (APRE) advances its novel macrocyclic ATR inhibitor into early-stage clinical studies for treating advanced solid tumors.
Amarin's (AMRN) Q4 Preliminary Revenues Top Expectations
by Zacks Equity Research
Amarin Corporation (AMRN) expects to generate total revenues in the range of $88-$90 million in fourth-quarter 2022. Share price rises following the announcement.
Regeneron (REGN) Down on Ophthalmology Drug Eylea Sales Update
by Zacks Equity Research
Regeneron's (REGN) lead drug Eylea's sales decline in the fourth quarter due to a short-term shift to off-label use of Avastin.
AstraZeneca (AZN) Set to Acquire CinCor Pharma for $1.3B
by Zacks Equity Research
AstraZeneca's (AZN) CinCor Pharma buyout is going to add blood pressure drug baxdrostat to its cardiorenal pipeline.
Sanofi (SNY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Sanofi (SNY) closed the most recent trading day at $48.51, moving +0.77% from the previous trading session.
FDA Accepts Pfizer's (PFE) sBLA Filing for Pneumococcal Jab
by Zacks Equity Research
The FDA grants priority review to Pfizer's (PFE) filing seeking label expansion of its pneumococcal 20-valent conjugate vaccine in infants and children. A decision is expected by this April.
Signet Jewelers and America's Car-Mart have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Signet Jewelers and America's Car-Mart have been highlighted as Zacks Bull and Bear of the Day.
FDA Accepts AstraZeneca (AZN), Sanofi's RSV Antibody BLA
by Zacks Equity Research
The FDA's decision on AstraZeneca (AZN)/Sanofi's (SNY) regulatory filing, seeking approval for using their RSV antibody in all infants, is expected in third-quarter 2023.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
What's in Store for Regeneron Pharmaceuticals (REGN) in 2023?
by Zacks Equity Research
Regeneron Pharmaceuticals (REGN) had a good run in 2022 and the momentum should continue in 2023 on the back of growth in Eylea and Dupixent.